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ings in most scenarios, the variation of IFX vial and ADA syringe costs are important 
factors that could modify the sensitivity analysis. ConClusions: The treatment 
of Crohn’s disease with ADA compared to IFX presented an economic savings for 
nearly 68% of patients with Crohn’s Disease in the Brazilian Private HealthCare 
System.
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objeCtives: To provide an open-access model and illustrate how this can be used 
as a first step in the early economic evaluation of emerging neuropathic pain 
products, enabling the understanding of important parameters in the assess-
ment of therapies. Methods: We closely replicated a model structure created 
by NICE to inform guideline development in neuropathic pain. The structure was 
replicated as R code for ease of exposition. Costs were updated to reflect 2014 
prices. The exploratory analysis considered a hypothetical drug ‘Product X’ versus 
pregabalin, a product used widely in neuropathic pain. The analysis explored the 
percentage premium over the price of pregabalin that would result in an ICER at 
the NICE threshold of £20,000 when varying efficacy parameters. Results: A 30% 
improvement over pregabalin in the proportion of patients achieving a 30-49% 
reduction in pain could justify a price premium of 39%, whilst a 30% improve-
ment in the proportion of patients achieving ≥ 50% improvement could justify a 
premium of 170%. If ‘Product X’ provides no analgesic improvement but causes 
30% fewer adverse events and related withdrawals, a premium of 27% could be 
justified. ConClusions: The analyses presented highlight how this transpar-
ent model can be used as a tool for identifying parameters of importance in the 
early economic evaluation in neuropathic pain. The R code underpinning these 
analyses is made readily available and we welcome the ISPOR community to 
use, adapt and provide comments on how to refine and improve this model for 
future use.
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objeCtives: Treatments for patients with moderate-to-severe ulcerative coli-
tis (UC) include biologic (adalimumab [ADA], infliximab [IFX], and golimumab 
[GOL]) and non-biologic therapies (anti-inflammatory drugs and immunosup-
pressants). Non-biologic therapy is standard of care (SOC). We evaluated the 
cost utility of ADA+SOC vs SOC alone and assessed the total cost difference 
of ADA+SOC vs IFX+SOC and GOL+SOC for treating moderate-to-severe UC in 
patients with inadequate response to non-biologic therapy in Spain. Methods: 
A Markov model was developed to simulate treatment and disease progression 
for UC patients, which considered 8 health states: 3 pre-surgery (remission, mild, 
and moderate-to-severe), surgery, and 4 post-surgery (no complication, transient 
complication, chronic complication, and death). The model assumed no differ-
ence in efficacy of biologic therapies. Transitional probabilities of pre-surgery, 
surgery and post-surgery states were derived from clinical trials of ADA and 
published literature. Health utility and cost inputs came from literature. Only 
direct costs were considered in the base case. Results were expressed in costs 
per quality-adjusted life-year (QALY) gained for ADA+SOC vs SOC alone and 
total cost differences for ADA+SOC vs IFX+SOC and GOL+SOC. Deterministic 
and probabilistic sensitivity analyses (DSA, PSA) were performed. Results: 
The incremental costs per QALY gained for ADA+SOC vs SOC alone were € 46,815 
over a 10-year time horizon (2013 euro). Results from DSA ranged from € 33,622 
(when indirect costs were considered) to € 49,083 (when the utilities of health 
states were changed). PSA revealed that ADA+SOC was cost-effective in 61% and 
84% of the simulations at € 50,000/QALY and € 60,000/QALY thresholds, respec-
tively. Compared with IFX+SOC and GOL+SOC, ADA+SOC was associated with 
cost savings of € 8,570 and € 37,113, respectively. DSA and PSA results showed 
that ADA+SOC led to cost savings in all scenarios. ConClusions: For UC, the 
ADA+SOC strategy demonstrated reasonable cost-effectiveness value compared 
with SOC alone and was cost-saving compared with IFX+SOC and GOL+SOC, in 
Spain.
PSY69
CoSt-utilitY of bariatriC SurgErY in bElgiuM, dEnMark, and italY
Borisenko O1, Burdukova E1, Hargreaves J2, Adam D1, Funch-Jensen P3
1Synergus AB, Stockholm, Sweden, 2Covidien (UK) Commercial Ltd, now part of Medtronic, 
Hampshire, UK, 3Aarhus University, and Aleris Hamlet Hospital, Aarhus, Denmark
objeCtives: To evaluate the cost-utility of bariatric surgery in Belgium, Denmark, 
and Italy from a third-party payer perspective over a 10-year and a lifetime hori-
zon. Methods: A state-transition Markov model was developed, in which patients 
may experience surgery, post-surgery complications, diabetes mellitus type 2, car-
diovascular diseases or die. Transition probabilities, surgery effectiveness and safety, 
costs, and utilities were informed by the literature, patient registries and adminis-
trative databases. Three types of surgeries were considered: gastric bypass, sleeve 
gastrectomy, and adjustable gastric banding. A base-case analysis was performed for 
the population of real surgical candidates in all countries. Cost data are presented 
in 2012 euros for Belgium, Italy and Denmark. Results: In Belgium, in the base-
case analysis over 10 years bariatric surgery led to incremental cost of € 3,261 and 
generated additional 1.4 quality-adjusted life years (QALYs) with incremental cost-
effectiveness ratio of € 2,407/QALY. Over lifetime, surgery led to savings of € 10,036, 
and generated additional 1.1 years of life, and 5.0 QALYs. In Denmark, in the base-
case analysis over 10 years bariatric surgery led to incremental cost of € 2,044 and 
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objeCtives: To compare costs and effectiveness of pregabalin compared to pla-
cebo in the treatment of central neuropathic pain (CNP) from the perspective of 
the public healthcare payer in the Czech Republic. Methods: A de novo micro-
simulation model was developed in MS Excel comparing pregabalin treatment of 
CNP versus placebo as there is no other treatment of CNP available and reimbursed 
in the Czech Republic. The improvement of patients’ pain intensity expressed 
as the decrease in VAS (Visual Analog Scale (0-100) score was modelled during 
the 24 week time horizon. The changes of VAS score were estimated for each 
intervention using a regression functions of time and the baseline VAS score. 
Utilities were assigned to each VAS score according to the regression equations 
expressing the dependence of utility value on average weekly VAS score of CNP 
patients. Relevant costs (reflecting payer’s perspective) were defined as costs of 
pharmacotherapies, outpatient care related to drug application, management of 
treatment, treatment of adverse events and concomitant medication were con-
sidered. Results: The incremental cost-effectiveness ratio (ICER) of pregabalin 
compared to placebo reached 8,335.22 EUR per Qualy-adjusted-life-year (QALY) 
gained. The probability of pregabalin being cost-effective (ICER under willing-
ness to pay 39,876.74 EUR) was 100%. ConClusions: Pregabalin is the only 
option for the treatment of CNP in the Czech Republic and brings significant pain 
relief for patients. Treatment with pregabalin also results in low ICER and can be 
considered a cost-effective treatment of central neuropathic pain in the Czech 
Republic.
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objeCtives: To evaluate the cost-effectiveness of ustekinumab in the treatment 
of psoriasis in the Finnish setting. Methods: A sequential Markov cohort model 
was programmed in Excel using Visual Basic for Applications. First, the most 
frequently used treatment sequence (ustekinumab -> adalimumab -> etaner-
cept -> infliximab -> maintenance, Finnish “current care”) was compared to the 
most used sequence prior to ustekinumab’s market authorization (adalimumab 
-> etenarcept -> infliximab -> maintenance, “past care” in Finland) in a con-
firmatory analysis setting. Then the incremental cost-effectiveness of all relevant 
treatment sequences was explored to find out the health economic relevance 
of current and past care sequences. The primary analysis outcomes were direct 
payer costs and quality-adjusted life years (QALY) gained. Secondary outcomes 
included Psoriasis Area and Severity Index (PASI) response years gained and 
Dermatology Quality of Life Index (DLQI) years avoided. Drugs, follow-up, drug 
administration, laboratory tests, adverse events and treatment failures as well 
as direct costs to patient were included as costs at 2014 price level. Initial treat-
ment efficacy was based on a Bayesian network meta-analysis of randomized 
clinical trials, and treatment persistence was modeled based on recent real 
world registry studies. All results were discounted with 3% per annum during 
the 5-year modelling timeframe. Results: The total discounted 5-year costs 
were € 74,383 for the current care and € 76,847 for the past care sequence. The 
respective QALYs were 3.895 and 3.825. Thus, the current care using ustekinumab 
dominated the past care without ustekinumab. PASI and DLQI results were in 
line with QALY results. Results were robust in the performed sensitivity analy-
ses. Furthermore, in the explorative analysis of all relevant treatment sequences, 
ustekinumab was always part of the cheapest sequence. ConClusions: 
Ustekinumab is the most cost-effective treatment in the current Finnish pso-
riasis treatment practice, and its use is both clinically and health economically 
relevant.
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objeCtives: The aim of this study was to describe the total treatment costs related 
to Crohn’s Disease treatment with biologics and to evaluate these costs based on 
the most prevalent weight range. Methods: A cost-minimization analysis was 
performed among adalimumab-subcutaneous (ADA) and infliximab-intravenous 
(IFX) to compare the total treatment costs in Crohn’s disease according to the 
Brazilian Private HealthCare System perspective. Total treatment cost was calcu-
lated based on the dose per application, number of vial/syringe, cost of application 
and median and range of weight. These inputs were based on scientific literature. 
Yearly treatment cost was calculated for patients with a median of 68kg, according 
to doses defined in product labels. A cost analysis for a weight range was per-
formed. Drug prices were based on Factory Prices plus 18% taxes (CMED source). An 
univariate analysis was performed to determine the impact on results. Results: 
The median patient weight used in this analysis was 68±4,08kg (Weight range: 
64 to 72kg - normal distribution). For IFX the Medication Cost was R$92.478,12, 
Application Cost was R$2.360,33 and the Total Treatment Cost was R$94.838,45. For 
ADA the Medication Cost was R$85.807,15, Application Cost was R$3.788,98 and the 
Total Treatment Cost was R$89.596,13. Comparing the scenario with IFX and ADA, 
the treatment with ADA presented a savings of R$5.242,32 per patient/year. The 
weight interval cost analysis presented a savings for ADA of R$5.242,32 per patient/
year in a range of 64 to 72kg. In sensitivity analysis ADA presented economic sav-
